Join        Login             Stock Quote

Intermune (ITMN) PT Lowered To $33 By Brean Murray As Esbriet Sales Come In Light

 April 27, 2012 01:55 PM

(By Balachander) Brean Murray, Carret & Co. (BMC) lowered its price target on shares of InterMune Inc. (NASDAQ:ITMN) to $33 from $37 and said shares remain substantially undervalued on a risk-adjusted cash flow basis.

The company reported a $47.6 million loss, ending the quarter with $377.2 million in cash and $240.3 million in convertible debt. Overall revenue was $8.9 million. BMC said ITMN's Esbriet lung disease drug sales of $4.9 million in 1Q12 missed its expectation of $7.5 million and consensus estimates of $5.9 million.

"Topline Esbriet sales came in short of dampened expectations....We expect the top-line miss to further fuel negative sentiment plaguing the stock in recent weeks," the brokerage wrote. BMC has a "Buy" rating on the stock.

[Related -Analysts' Rating And Target Changes: AAPL, BA, DELL, ITMN, K, MOS, YELP]

"Although an actual breakout of new patient starts put the quarter in a more positive light, we see the decrease in new starts in Germany relative to last quarter as a disappointment and are adjusting our growth trajectory accordingly," BMC said.

The brokerage believes the last four months of the year will be a source of significant upside as it gets clarity on pricing in Germany, France, Italy and Spain. "Although it is possible that French pricing could come in earlier than September, we believe a September 15 price determination in Germany will recognize the value of Esbriet, albeit at a 10 percent - 20 percent discount to the current $40k per patient/year net price," BMC said.

[Related -Strong Pre-Election Session]

InterMune shares, which have been trading in the 52-week range of $9.66 to $46.13, tumbled 17.5 percent to trade at $10.27 on Friday.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageOld Bank's New Breakout has Big Rally Potential

One of my favorite things to see in a long candidate is a pattern of beating Wall Street's earnings read on...

article imageIs The Stock Market's 5-Year Return A Useful Proxy For Valuation?

Tobin’s Q, a market-valuation metric, is back in the news, in part thanks to a widely read Bloomberg read on...

article image4 Dogs To Sell Immediately

Despite the chorus of analysts and investors calling for the long-awaited correction, the market is showing read on...

article imageThe Fed's Magical Mystery Tour

What's going on at the Fed? Notorious dove, Charles Evans of the Chicago Fed, gave a speech in read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

Mixed Day With Positive Technicals
More Articles on: Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.